NeuroPace Inc (NPCE) earnings date
Mar 2, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 43 days, typically, give or take 10 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Thu, Nov 12, 2026 | after close | 43 | 8-K |
| Q2 FY2026 | Tue, Aug 11, 2026 | after close | 42 | 8-K |
| Q1 FY2026 | Tue, May 12, 2026 | after close | 42 | 8-K |
| Q4 FY2025 | Tue, Mar 3, 2026 | after close | 62 | 8-K |
| Q3 FY2025 | Tue, Nov 4, 2025 | after close | 35 | 8-K |
| Q2 FY2025 | Tue, Aug 12, 2025 | after close | 43 | 8-K |
| Q1 FY2025 | Tue, May 13, 2025 | after close | 43 | 8-K |
| Q4 FY2024 | Tue, Mar 4, 2025 | after close | 63 | 8-K |
What they guided beta
| Q3 FY2026 | "Document NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on improving commercial execution and accelerating growth Advances innovation pipeline with NeuroPace Remote Care™ FDA submission and upcoming IGE PMA-S Amendment, supporting significant long-term growth opportunities Mountain View, Calif. – November 12, 2026 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device comp" exhibit |
| Q3 FY2026 | "Data collection is expected to be completed in early 2027, followed by analysis and submission to the FDA." exhibit |
| Q3 FY2026 | "Full Year 2026 Financial Guidance" exhibit |
| Q3 FY2026 | "Revise total revenue guidance for full year 2026 to between $91 million and $92 million, representing underlying RNS growth of 10% to 11%." exhibit |
| Q3 FY2026 | "Revise full year non-GAAP operating expenses to be between $85 million and $86 million, compared to previous guidance of $90 million to $92 million." exhibit |
| Q2 FY2026 | "Document NeuroPace Reports Second Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Q2 2026 total revenue of $22.8 million, including $22.5 million in RNS revenue representing 21% growth Raises full year 2026 total revenue guidance to $99.5 million to $101.5 million, which assumes 21% to 23% growth in core RNS ® revenue from existing indications Preparation remains on track for SIR meeting with FDA regarding the IGE PMA supplement, supported by 24-month NAUTILUS data showing a 100% median reduction in GTC seizures among evaluable patients 1 Mountain View, Calif. – August 11, 202" exhibit |
| Q2 FY2026 | "Full Year 2026 Financial Guidance" exhibit |
| Q2 FY2026 | "Increase total revenue guidance for full year 2026 to between $99.5 million and $101.5 million, compared with previously issued guidance of $99 million to $101 million." exhibit Read from the sentence: revenue $99.5 million to $101.5 million, FY2026 |
| Q2 FY2026 | "Reiterate full year non-GAAP operating expenses to be between $90 million and $92 million, excluding approximately $10 million in stock-based compensation, a non-cash expense" exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/NPCE
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/NPCE
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/NPCE/"><img src="https://veritasdata.dev/embed/NPCE.svg" alt="NPCE earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/NPCE/)
Script
<script async src="https://veritasdata.dev/embed/NPCE.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/NPCE"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.